Use of cyclosporin in psoriasis
- PMID: 2574777
- DOI: 10.1016/s0140-6736(89)92941-3
Use of cyclosporin in psoriasis
Abstract
In the treatment of severe psoriasis, cyclosporin may achieve improvement or remission at low doses, but relapse usually occurs on withdrawal of treatment. An initial dose of 3 mg/kg per day is recommended. Complete remission should not be the objective, and the role of long-term maintenance cyclosporin therapy is uncertain because of potential side-effects--especially nephrotoxicity, hypertension, and a predisposition to malignancy. Guidelines are proposed for the assessment of such treatment.
Comment in
-
Cyclosporin monitoring in psoriasis.Lancet. 1990 Apr 7;335(8693):866-7. doi: 10.1016/0140-6736(90)90990-m. Lancet. 1990. PMID: 1969599 No abstract available.
Similar articles
-
Long-term treatment of severe psoriasis with low-dose cyclosporin: (2.5 mg/kg/day to 5 mg/kg/day).Acta Derm Venereol Suppl (Stockh). 1989;146:147. Acta Derm Venereol Suppl (Stockh). 1989. PMID: 2692369 Clinical Trial. No abstract available.
-
Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis.Br J Dermatol. 1990 Sep;123(3):347-53. doi: 10.1111/j.1365-2133.1990.tb06295.x. Br J Dermatol. 1990. PMID: 2206973
-
Long-term treatment of psoriasis with cyclosporin A--side-effects, minimal effective dose and cyclosporin blood levels.Clin Exp Dermatol. 1991 Jan;16(1):8-10. doi: 10.1111/j.1365-2230.1991.tb00283.x. Clin Exp Dermatol. 1991. PMID: 1902760
-
Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience.Br J Dermatol. 1990 Jun;122 Suppl 36:21-5. doi: 10.1111/j.1365-2133.1990.tb02878.x. Br J Dermatol. 1990. PMID: 2196080 Review.
-
Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands.Br J Dermatol. 1990 Jun;122 Suppl 36:27-31. doi: 10.1111/j.1365-2133.1990.tb02879.x. Br J Dermatol. 1990. PMID: 2196081 Review.
Cited by
-
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.J Exp Med. 1994 Jul 1;180(1):283-96. doi: 10.1084/jem.180.1.283. J Exp Med. 1994. PMID: 7516410 Free PMC article.
-
The Brain-Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System.Cells. 2020 Mar 26;9(4):796. doi: 10.3390/cells9040796. Cells. 2020. PMID: 32224981 Free PMC article. Review.
-
Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.Drugs. 1993 Jun;45(6):953-1040. doi: 10.2165/00003495-199345060-00007. Drugs. 1993. PMID: 7691501 Review.
-
Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?Drug Saf. 1999 Apr;20(4):289-97. doi: 10.2165/00002018-199920040-00001. Drug Saf. 1999. PMID: 10230579 Review.
-
Unraveling the Potential of Vitamin B3-Derived Salts with a Salicylate Anion as Dermal Active Agents for Acne Treatment.Mol Pharm. 2024 Sep 2;21(9):4634-4647. doi: 10.1021/acs.molpharmaceut.4c00543. Epub 2024 Aug 14. Mol Pharm. 2024. PMID: 39141824 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical